Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- WEBSITE NWES
October 25, 2004
- EFPIA Survey Finds Problems in Clinical Trial Environment
October 25, 2004
- Korosho to Consider 8-Year Data Protection Period in Earnest
October 25, 2004
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
October 25, 2004
- Production Value of Drugs Rose 0.7% in 2003
October 25, 2004
- OTC NEWS IN BRIEF
October 25, 2004
- Notification Explains Requirements for Interviews on Review Progress
October 25, 2004
- MONITOR
October 25, 2004
- 2nd Committee on Drugs Recommends Approval of Aredia
October 25, 2004
- BULLETIN
October 25, 2004
- REGULATORY NEWS IN BRIEF
October 25, 2004
- DIAGNOSTIC NEWS IN BRIEF
October 25, 2004
- 3Qtrs Business Results
October 25, 2004
- Business Forecast
October 25, 2004
- Business Forecast
October 25, 2004
- WORLD NEWS IN BRIEF
October 25, 2004
- 55th WMA General Assembly
October 25, 2004
- Necessary to Further Open the Way to Mixed Medical Care: Health Minister Otsuji
October 25, 2004
- Ministries to Cooperate to Develop Nanotech in Healthcare Field
October 25, 2004
- NER PRODUCTS
October 25, 2004
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…